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The primary structure of a novel human chrcmogranin A-derived tetradecapcptide, WE-14, possessing N-terminal tryptophanyl (W) and C-terminal 
glutamyl (E) residues was isolated from a hcpatic metastasis of an human ileal carcinoid tumour. Human and bovine WE-14 are structurally 
identical, while rat, mouse and porcine analogues exhibit 93% homology, WE-14 is flanked by paired basic residues (KR) in all known chromogranin 
A sequences. 
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1. INTRODUCTION 
T!?e determhwtion of the cDNA sequences of chro- 
mogranin A from several species of mammal, revealed 
the presence of seven conserved pairs of basic amino 
acids which represent potential proteolytic processing 
sites [l-5]. These structural characteristics would sug- 
gest that chromogranin A may be a precursor of poten- 
tially-bioactive peptides. This hypothesis was supported 
by the discovery of porcine pancreastatin [[i], which 
exhibited a high degree of structural homology with a 
region of bovine chromogranin A [l]. In addition, there 
is increasing evidence that chromogranin A undergoes 
tissue-specific proteolytic processing [7,8] and that chro- 
mogranin A-derived peptides exhibit biological activity 
[g-12]. A comparison of the five known mammalian 
chromogranin A primary structures revealed that a 
highly-conserved tetradecapeptide, WE-14 (N-terminal 
tryptophanyl (W) and a C-terminal glutamyl (E) resi- 
due), is flanked by putative paired basic residue (KR) 
processing sites (Fig. 1). In Ihis study, we report the 
isolation and primary structure of WE-14 from a he- 
patic metastasis of a human ileal carcinoid turnour. 
2. MATERIALS AND METHODS 
2. I, Rudioiritntlcnoas~uJ~ 
Aniisera were raised to the conserved C-terminal hcxapcptidc of 
WE-14, designated KELTAE [S], incorporating an N-terminal tyrosyl 
residue to facilitate radioiodination. Radioiodinated tracer was prc- 
pared using Iodogen and the product was resolved by reverse-phase 
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HPLC. One rabbit (R635) produced asensitive anliserum which was 
employed in radioimmunoassay ta final dilution of I:l2.000. The 
assay was carried out in a 40 mmolll sodium acetate buffer, pH 6.0. 
containing 0,2% (w/v) bovine serum albumin, in a total volume of 300 
yl comprising 100 ~1 antiserum (l/4000), 100~1 tracer (100 Bq: 2 pg) 
and 100 ~1 of synthetic pcptidc standard (I-250 pdassay tube) or 
sample. After addition of all reactants, assays were incubated for 24 
h at 4°C. Bound and free pptides wcrc scparatcd by dextran-coated 
chnrcoal and ccntrifupation. Pellets werecounted on a Nuclear Enter- 
prises NE 1600 gamma counter. The cross-reactivity of the antiserum 
was assessed with a wide range of pstro-entero-pancreatic peptide 
hormones. No cross-reactivity was detected. 
2.2. Peptide isoluriort 
The hcpatic metastasis was obtained at laparotomy from a 60-year- 
old male with a primary ileal carcinoid tumour. Tissue was snap- 
frozen in liquid nitrogen and stored at -80°C prior to extraction. 
Tumour tissue (9 g) was homogcniscd in the extraction medium (cth- 
anal/0.7 mol/l HCI; 3:1 (v/v); 8 ml/g tissue), slirred overnight at 4°C 
and centrifuged to remove tissue debris. Ethanol was removed from 
the supernatant under reduced pressure. Peptides in the remaining 
acidic solution were cc;ncentrated using Sep-Pak C-l 8 cartridges (Wa- 
tcrs Associates, Milford, MA, USA). Bound pcptiJes wrrccluted with 
acetonitrilc and the &ant was lyophilised. The lyophylisate was re- 
constituted in 2 ml of 2 M acetic acid prior to gel permeation chrom- 
atography (Scphadex G-50 fine, 90 x 1.6 cm column, flow rate 10.4 
ml/h, mobile phase 2 M acetic acid, fraction size 3 ml). Fraclions were 
subjected to KELTAE radioimmunoassay and peak-immunoreactive 
fractions were purified to homogcncity employing the following se- 
quence of reverse phase HPLC columns: (I) Partisil IO ODS-3, C-18. 
1 x 60 cm (Whatman. Kent, UK); flow rate 3 ml/min; (2) Supelcosil 
Lc-308, C-8, 0.46 x 25 cm (Supelco Inc., Bellfontc, PA, USA). flow 
rate I.5 mllmin. The gradients employed were generated using tri- 
fluoroacetic acid (TFA)/water and TFA/water/acetonitrile as indi- 
cated in Fig. 3a and b. The purification of the KELTAE-immunoreac- 
tivc peptide was monitored by radioimmunoassay nd spectro- 
photometrically at 214 nm and 380 nm (Figs. 2 and 3). 
2.3, Structural aaolyscs 
Spectrophotometrically-homopnous peptidc was dissolved in 0.1% 
(v/v) aqueous TFA and I.5 nmol was applied to a nitroccllulose- 
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WE-14 
Human 322 KR WSKMDQLAKELTAE KR 339 
Bovine 314 -- ----_--_~_---- -- 331 
Rat 341 -_ --R----------- -- 358 
Mouse 338 -- --R----------- -- 355 
Porcine 311 -- ----_ R -_------ -- 327 
Fig 1. The primary structure of human WE-14. which is flanked‘by 
paired basic amino acid (KR) residues, and the corresponding WE-14 
sequences deduced from cDNA analysis of bovine [2], rat [3], mouse 
[4] and porcine [S] chromogranin A. 
covered target which was spin-dried and micro-rinsed prior to 2%f- 
plasma desorplion mass pectroscopy (Biolon 2OK time-of-Right in- 
strument). Spectra were recorded at 16 kV for 1Ob primary fission 
events. The remaining peptide was subjected to automated Edman 
degradation (Applied Biosystem 470A gas phase sequencer). 
3. RESULTS 
3.1. Peptide isoiatiotl 
KELTAE immunoreactivity was abundant in the 
crude-tissue xtract (74 pg/g) and a single immunoreac- 
tive peptide was resolved by gel permeation chromatog 
raphy (Fig. 2). Sequential reverse phase HPLC of the 
single peak immunoreactive gel permeation fraction re- 
solved a single spectrophotometrically-homogeneous 
peptide (Fig. 3a and b). Approximately 10 nmol of im- 
munoreactive peptide was purified to apparent homoge- 
neity. 
3.2. Srrucrural analyses 
Plasma desorption mass spectroscopy detected a sin- 
gle ion with a calculated molecular mass of 1649.5 Da, 
which compares favourably with the expected molecu- 
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Fig. 2. Gel permeation chromalogram of WE-14 immunoreactivity in
extracts of the hepatic metastasis of the human heal carcinoid. The 
column was calibrated with Blue dextran (Vo) and potassium dichro- 
mate (Vt). 
t 
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Fig. 3, Final reverse phase HPLC (Supclcosil LC-308) profile of WE- 
14 immunoreactivity (arrow) monitored at (a) 214 nm and(b) 280 nm. 
lar mass of 1649.9 Da. Automated Edman degradation 
established unequivocally the sequence of residues 2 to 
14. A non-identified PTH amino acid was observed in 
cycle 1 which might’represent an oxidized tryptophan 
residue or another tryptophan derivative generated in 
the sequencer (Table I). Spectrophotometric monitoring 
of the peptide during isolation indicated a 280 nm ab- 
sorbance consistent with the presence of a tryptophan 
residue. The molecular mass is consistent with this as- 
signation as is the primary structure of WE-14 previ- 
ously established by human chromogranin A cDNA 
analysis. 
Table I 
Amino acid scqucnce of human WE-14 
- 
Cycle No PTH amino acid 
1 (Trp)” 
2 Ser 
3 Lys 
4 Met 
5 Asp 
7” Gln Leu 
8 Ala 
9 LYS 
IO Glu 
II Leu 
12 Thr 
13 Ala 
14 GlU 
Yield (pmol) 
381 
829 
1352 
588 
938 87
913 
524 
47s 
654 
279 
435 
112 
*A non-identified PTH amino acid was seen in cycle No. 1, which may 
represent an oxidized tryptophan or another tryptophan-derivative 
generated in the sequencer 
320 
Volume 301, number 3 FEBS LETTERS April 1992 
4. DISCUSSION 
Sequence analysis of peptides derived from in vivo [7] 
and in vitro [13] processing of bovine chromogranin A 
have demonstrated that cleavuge occurred at the pairs 
of basic residues, 314-3 15 and 330-33 1, flanking bovine 
WE-14, further supporting the proteolytic cleavage of 
human WE-14. The human and bovine peptides are 
homologous. Human, rat, mouse and porcine WE-14 
exhibit 93% homology. The rat and mouse peptides are 
identical and differ from the human by a single amino 
acid substitution (Lys for Arg at residue 3), while simi- 
larly, the human and porcine peptides differ by a single 
substitution (Gln for Arp at residue 6) Unlike other 
chromogranin A-derived peptides, such as pancreas- 
tatin [7,14,15] and chromostatin [12], WE-14 is flanked, 
both N-terminally and C-terminally by typical process- 
ing sites and exhibits a high degree of inter-specific con- 
servation of primary structure. Such factors would sug- 
gest that this peptide has a potential physiological role 
in mammals. 
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